Security
SCYX · SCYNEXIS INC
SCYXNASDAQCommon stockCurrentCIK 1178253Updated Sep 24, 2026
SCYX price & chart
Loading TradingView…
NASDAQ:SCYX on TradingView ↗About the company
SCYNEXIS, Inc. (NASDAQ: SCYX) is a clinical stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com.
In the news
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4) ↗
Seeking Alpha
SCYNEXIS to implement 1-for-8 reverse stock split ↗
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow ↗
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript ↗
Recent filings
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD Disclosure
Items 5.02, 7.01, 9.01
4 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Items 5.02, 8.01
SCHEDULE 13G/A filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 59,027,000Source | 90,643,000Source | 128,412,000Source | 87,810,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | 0Source | 408,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 21,259,000Source | 16,051,000Source | 34,050,000Source | 45,814,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | 0Source | 2,101,000Source |
| Inventory, NetUSD | — | — | 0Source | 899,000Source |
| Assets, CurrentUSD | 40,374,000Source | 72,181,000Source | 102,116,000Source | 79,061,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 263,000Source | 2,184,000Source | 5,548,000Source | 2,503,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,764,000Source | 2,090,000Source | 2,364,000Source | 2,594,000Source |
| Other Assets, NoncurrentUSD | — | — | 0Source | 5,511,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 9,651,000Source | 35,566,000Source | 55,450,000Source | 84,577,000Source |
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | 434,474,000Source | 431,571,000Source | 428,169,000Source | 425,485,000Source |
| Retained Earnings (Accumulated Deficit)USD | -385,144,000Source | -376,535,000Source | -355,247,000Source | -422,288,000Source |
| Stockholders' Equity Attributable to ParentUSD | 49,376,000Source | 55,077,000Source | 72,962,000Source | 3,233,000Source |
| Liabilities and EquityUSD | 59,027,000Source | 90,643,000Source | 128,412,000Source | 87,810,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 5,734,000Source | 24,099,000Source | 16,303,000Source | 17,618,000Source |
| Operating Lease, Liability, CurrentUSD | 483,000Source | 407,000Source | 340,000Source | 282,000Source |
| Accounts Payable, CurrentUSD | 2,225,000Source | 4,569,000Source | 7,149,000Source | 5,937,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,692,000Source | 2,175,000Source | 2,581,000Source | 2,921,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | 0Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 2,791,000Source | 3,793,000Source | 7,495,000Source | 5,628,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 56,300,000Source | 75,100,000Source | 98,000,000Source | 73,500,000Source |
| Deferred Revenue, CurrentUSD | 235,000Source | 1,642,000Source | 1,189,000Source | — |
| Deferred Revenue, NoncurrentUSD | 0Source | 1,294,000Source | 2,727,000Source | — |
| Short-term InvestmentsUSD | 18,772,000Source | 43,249,000Source | 40,312,000Source | 27,689,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,852,000Source | 3,346,000Source | 2,624,000Source | 3,686,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | 0Source | -2,101,000Source | 1,240,000Source |
| Increase (Decrease) in InventoriesUSD | — | 0Source | 8,849,000Source | 436,000Source |
| Increase (Decrease) in Accounts PayableUSD | -2,234,000Source | -2,650,000Source | 1,172,000Source | -1,481,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -5,283,000Source | -24,009,000Source | 60,159,000Source | -79,883,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 24,306,000Source | 6,150,000Source | -34,877,000Source | -27,389,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -14,170,000Source | -139,000Source | -36,721,000Source | 48,602,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 21,448,000Source | 16,595,000Source | 34,593,000Source | 46,032,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 420,000Source | 840,000Source | 3,248,000Source | 5,190,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 2,852,000Source | 3,346,000Source | 2,624,000Source | 3,512,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 312,000Source | 1,726,000Source | 2,994,000Source | 1,589,000Source |
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 700,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 56,300,000Source | 75,100,000Source | 98,000,000Source | 73,500,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | 196,000Source | -154,000Source | 1,316,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| InterestExpenseNonoperatingUSD | 173,000Source | 828,000Source | — | — |
| Inventory Write-downUSD | — | 0Source | 14,577,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Nonoperating Income (Expense)USD | 7,465,000Source | 15,980,000Source | -5,490,000Source | 18,248,000Source |
| Operating ExpensesUSD | 36,675,000Source | 40,863,000Source | 67,472,000Source | 90,848,000Source |
| Proceeds from Issuance of Common StockUSD | 5,000Source | — | 0Source | 47,248,000Source |
| Proceeds from Stock Options ExercisedUSD | 0Source | 0Source | 0Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 20,601,000Source | 3,746,000Source | 140,141,000Source | 5,091,000Source |
| Selling, General and Administrative ExpenseUSD | 14,395,000Source | 14,458,000Source | 20,920,000Source | 62,961,000Source |
| Operating Income (Loss)USD | -16,074,000Source | -37,117,000Source | 72,669,000Source | -85,757,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,609,000Source | -21,137,000Source | 67,179,000Source | -67,509,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| Net Income (Loss) Attributable to ParentUSD | -8,609,000Source | -21,288,000Source | 67,041,000Source | -62,809,000Source |
| Earnings Per Share, BasicUSD per share | -0.17Source | -0.44Source | 1.4Source | -1.47Source |
| Earnings Per Share, DilutedUSD per share | -0.17Source | -0.44Source | 1.39Source | -1.47Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 49,933,381Source | 48,513,073Source | 47,852,833Source | 42,613,510Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 49,933,381Source | 48,513,073Source | 48,390,582Source | 42,613,510Source |
| Interest Expense (non-operating)USD | 173,000Source | 828,000Source | — | — |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 400,000Source | 700,000Source |
| Current Income Tax Expense (Benefit)USD | 0Source | 151,000Source | 138,000Source | -4,700,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | 0Source | 580,000Source | 606,000Source |
| Gain (Loss) on Derivative Instruments, Net, PretaxUSD | 0Source | 196,000Source | -154,000Source | 1,316,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -4,700,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 3,130,000Source | 5,198,000Source |
| Interest Income, OtherUSD | 2,177,000Source | 4,291,000Source | 3,954,000Source | 1,415,000Source |
| Nonoperating Income (Expense)USD | 7,465,000Source | 15,980,000Source | -5,490,000Source | 18,248,000Source |
| Operating ExpensesUSD | 36,675,000Source | 40,863,000Source | 67,472,000Source | 90,848,000Source |
| Research and Development ExpenseUSD | 22,280,000Source | 26,405,000Source | 30,928,000Source | 27,259,000Source |
Filing attachments
scyx-ex99_1.htm · 8-K · 2026-09-22
Exhibit 99.1 SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industry JERSEY CITY, N.J., September 22, 2026 - SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to i…
Read attachment ↗scyx-ex99_1.htm · 8-K · 2026-09-10
EX-99.1 2 scyx-ex99_1.htm EX-99.1 EX-99.1 SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies. JERSEY CITY, N.J., September 10, 2026 - SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare di…
Read attachment ↗d114312dex991.htm · 8-K · 2026-03-31
EX-99.1 2 d114312dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Advancing innovative solutions for severe rare diseases Corporate Deck March 2026 Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc. (the “Company”) solely for informational purposes. This presentation contains, and our officers and representatives may from time to time make, “forward-looking statements” within the meaning of applicable securities laws and are prospective in nature, including, but not limited to,…
Read attachment ↗d122408dex41.htm · 8-K · 2026-03-31
EX-4.1 2 d122408dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (…
Read attachment ↗d122408dex42.htm · 8-K · 2026-03-31
EX-4.2 3 d122408dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) …
Read attachment ↗d122408dex991.htm · 8-K · 2026-03-31
EX-99.1 6 d122408dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 SCYNEXIS Announces $40.0 million Private Placement JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) - SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that it has entered into a securities purchase agreement with certain new an…
Read attachment ↗